Recursion Pharmaceuticals
Recursion Pharmaceuticals / recursion.com
AI-driven drug discovery company using high-throughput cellular imaging and machine learning to identify drug candidates at biological scale, with a dataset of trillions of cellular images.
Pricing
Free
Free plan
No
Category
Developer Tools
Platforms
2
Free plan
No
API access
No
Open source
No
Platforms
2
Advertisement
What is Recursion Pharmaceuticals?
Recursion Pharmaceuticals is an AI drug discovery company that takes a distinctly data-driven approach — running millions of cellular biology experiments automatically and analysing the resulting high-content imaging data with machine learning to identify drug candidates at a scale no human research team could achieve.
The Recursion OS is the proprietary platform combining automated laboratory robotics, high-content cellular imaging at massive scale, and machine learning models trained on trillions of cellular images. The platform has imaged approximately 50 trillion cells across millions of experiments, building the largest proprietary biological dataset for AI drug discovery.
The core insight is that cellular phenotypes — how cells look under microscope imaging — encode biological information about disease mechanisms and drug effects. By systematically perturbing millions of biological conditions (genetic knockouts, drug treatments, disease models) and imaging the cellular responses, Recursion builds a map of biological space that AI models can navigate to identify patterns predictive of drug effects.
Recursion's pipeline includes candidates in oncology, rare diseases, and infectious diseases. The company has partnerships with major pharmaceutical companies including Roche, Bayer, and Sanofi for applying its platform to specific therapeutic programmes.
At scale, Recursion's approach represents a different thesis than AI drug design companies like Insilico Medicine — Recursion focuses on biological discovery through empirical measurement at scale, while Insilico focuses on generative chemistry from biological targets.
How Recursion Pharmaceuticals works
Recursion Pharmaceuticals runs as computer vision software built around image and data workflows. Users typically start with a prompt, upload, or connected data source, and the underlying model handles the heavy lifting before returning a result you can refine or export. It's available on web and api.
Watch Recursion Pharmaceuticals in action
Recent YouTube videos cached from the backend so this page stays fast and fresh.
What makes it worth shortlisting
The capabilities that matter most for teams evaluating Recursion Pharmaceuticals.
Recursion OS
Automated platform combining robotic wet laboratory experiments, high-content cellular imaging at scale, and machine learning analysis of the resulting biological data.
Trillion-cell biological dataset
Approximately 50 trillion imaged cells from millions of perturbation experiments form a proprietary biological dataset mapping the relationship between biological conditions and cellular phenotypes.
Pharmaceutical partnerships
Collaboration programmes with major pharmaceutical companies applying the Recursion OS to specific therapeutic programmes in oncology, rare diseases, and other areas.
Best use cases
Who should use it
Pros
- Trillion-cell dataset scale is unmatched for AI biological discovery — the data moat is exceptional
- Automated lab platform generates new data continuously rather than relying only on historical datasets
- NVIDIA partnership provides access to BioNeMo biological foundation models for enhanced predictions
- Pharmaceutical partnerships with Roche, Bayer, and Sanofi validate platform credibility
Cons
- Drug discovery timelines are inherently long — AI acceleration is measured in years
- Clinical success probability remains uncertain across the entire drug discovery industry
- Publicly traded company (RXRX) — review financial performance and analyst coverage before partnership commitments
Advertisement
Is it worth the price?
Pharmaceutical partnership programmes. No public pricing or individual access. Publicly traded on NASDAQ (RXRX).
Model
Enterprise
Starting price
Free
Free trial
No
Tools like Recursion Pharmaceuticals
Insilico Medicine (covered, rank 320) focuses on generative chemistry. Schrödinger provides computational chemistry and structure-based design. Exscientia uses AI for drug design at clinical scale. PathAI focuses on pathology diagnostics rather than drug discovery.
Recursion Pharmaceuticals vs Bioptimus AI
A side-by-side look at the closest alternative in this category.
Recursion Pharmaceuticals
Recursion Pharmaceuticals
Bioptimus AI
Bioptimus
Pharmaceutical partnership programmes. No public pricing or individual access. Publicly traded on NASDAQ (RXRX).
Research and pharmaceutical partner access. No public pricing. Contact for partnership information. Raised $35M+ in funding.
Enterprise research data handling agreements. GDPR compliant. Publicly traded company (RXRX) with standard public company disclosures.
Research data handling agreements. GDPR compliant (French company). Enterprise partnership data handling agreements.
Recursion processes biological research data under enterprise partnership data handling agreements.
Review Bioptimus's data handling policy for research partnerships. Biological and patient data processed under applicable research ethics and data protection frameworks.
- Trillion-cell dataset scale is unmatched for AI biological discovery — the data moat is exceptional
- Automated lab platform generates new data continuously rather than relying only on historical datasets
- NVIDIA partnership provides access to BioNeMo biological foundation models for enhanced predictions
- Pharmaceutical partnerships with Roche, Bayer, and Sanofi validate platform credibility
- Frontier biological AI development with a clear vision for universal biological foundation models
- H-optimus-0 pathology model is publicly available for research evaluation
- French and European positioning for the growing European life sciences AI market
- Strong academic founding team and pharmaceutical partnership interest validate approach
- Drug discovery timelines are inherently long — AI acceleration is measured in years
- Clinical success probability remains uncertain across the entire drug discovery industry
- Publicly traded company (RXRX) — review financial performance and analyst coverage before partnership commitments
- Very early stage — limited commercial availability and unproven at pharmaceutical deployment scale
- Foundation model for biology is a long-term research bet rather than near-term commercial product
- Clinical validation of model outputs is a significant ongoing requirement for pharmaceutical applications
Technical & deployment info
Key facts about model providers, platforms, and team support.
Model Provider
Recursion
Platforms
Web, API
Deployment
Enterprise
Integrations
NVIDIA BioNeMo, Pharmaceutical partner systems, API
Team Collaboration
No
Launch Year
2020
Security & privacy
Compliance signals and data-handling notes as reported by the vendor.
Enterprise research data handling agreements. GDPR compliant. Publicly traded company (RXRX) with standard public company disclosures.
Recursion processes biological research data under enterprise partnership data handling agreements.
What users are saying
Verified reviews from signed-in users, stored in the backend and averaged into this tool's rating.
Sign in to rate Recursion Pharmaceuticals and leave a review.
No other reviews yet — be the first to share how this tool performs in practice.
Common questions about Recursion Pharmaceuticals
Editorial Verdict
Should you use Recursion Pharmaceuticals?
Recursion is the most data-rich AI drug discovery platform for pharmaceutical companies seeking partnerships that leverage empirical biological measurement at scale for candidate identification.
Last verified July 24, 2026.